NAD+ Supplement Eases Menopausal Symptoms in Just Seven Days, Pilot Study Finds

NAD+ has long been central to longevity research, associated with energy metabolism, cellular repair, and age-related decline. Menopause research, by contrast, has mostly occupied a separate lane focused on hormones and symptom relief. A new pilot study from Elysium Health suggests these two fields may be converging in ways that matter for women's healthspan.

The open-label study, published in Frontiers in Aging, enrolled 40 healthy women over 35. Thirty-two were experiencing menopausal symptoms; eight reported few or none. After seven days of taking Basis — Elysium's flagship supplement containing NR and pterostilbene — symptomatic women reported reductions of 50% or more in the frequency and severity of hot flashes, bloating, and poor sleep. That timeline is unusually short for supplement research and distinguishes this work from typical trials requiring months before effects are detectable.

Beyond subjective symptom relief, researchers measured a biological signal: an increase in the ratio of estradiol to estrone. These are two closely related forms of estrogen whose balance shifts during the menopause transition. The team hypothesizes that supporting NAD+ metabolism may help promote a healthier hormonal balance, rather than simply boosting total estrogen levels. The study's lead researcher, Dr. Marie Migaud, noted the investigation was partly inspired by her own experience using Basis during menopause.

Additionally, the study identified a previously unreported NAD+ metabolite, adding to scientific understanding of how the molecule is processed inside the body — a finding that may carry implications beyond menopause.

Caveats are significant. This is a small, open-label pilot with no placebo arm, meaning placebo effects cannot be ruled out. Elysium Health, which sells Basis commercially, sponsored the research, introducing potential conflicts of interest. The authors themselves call for larger, randomized, placebo-controlled trials. Still, the rapidity of symptom improvement and the hormonal signal make this a credible prompt for serious follow-up investigation.